Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL925122 | 0.98 | KMT2A (0.47) | KMT2AMEN1POLBMAPTCYP1A2 | |
| SCHEMBL1493339 | 0.82 | SMN1; SMN2 (0.50) | KMT2AMAPTCYP1A2CRHBPCRHR2 | |
| SCHEMBL19924700 | 0.81 | SMN1; SMN2 (0.53) | KMT2AMAPTCYP1A2CRHBPCRHR2 | |
| Hydrochloric Acid SCHEMBL923005 | 0.81 | SMN1; SMN2 (0.49) | KMT2AMEN1POLBMAPTCYP1A2 | |
| SCHEMBL922677 | 0.78 | HRH4 (0.50) | — | |
| SCHEMBL14822948 | 0.78 | KMT2A (0.49) | KMT2AMEN1POLBCRHBPCRHR2 | |
| SCHEMBL13815773 | 0.75 | CNR2 (0.53) | — | |
| SCHEMBL19367479 | 0.74 | CRHBP (0.55) | KMT2AMEN1POLBMAPTCYP1A2 | |
| SCHEMBL9972764 | 0.74 | KMT2A (0.41) | KMT2AMEN1POLBMAPTCYP1A2 | |
| SCHEMBL15821626 | 0.73 | KMT2A (0.44) | KMT2AMEN1POLBMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118894856-A | Pyrazole-containing polycyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-118894855-A | Pyrazole-containing polycyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-114222746-B | Pyrazole-containing polycyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20230118497-A1 | PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| EP-4074714-A1 | PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-10-19 | — | — | EP | disclosed |
| CN-114222746-A | Pyrazole-containing polycyclic derivative inhibitor, and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2021115225-A1 | PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2021-06-17 | — | — | WO | disclosed |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| CN-101405289-A | Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof | WYETH CORP (US) | 2009-04-08 | — | — | CN | disclosed |
| EP-1996594-A2 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007109093-A2 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | WYETH (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219186-A1 | Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | KMT2A 2931/4885MEN1 3936/4885POLB 1521/4885 |
| US-20230118497-A1 | PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX4 | KMT2A 4250/4885MEN1 1578/4885POLB 3811/4885 |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | MKI67, CDK4, CCNC | KMT2A 4148/4885MEN1 1844/4885POLB 1409/4885 |
| US-20070219186-A1 | Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof | DPYD, TYMP, TYMS | KMT2A 2711/4885MEN1 2762/4885POLB 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.